温热腹腔化疗
医学
卵巢癌
外科肿瘤学
腹腔化疗
细胞减少术
化疗
顺铂
肿瘤科
热疗
围手术期
内科学
癌症
普通外科
外科
作者
Julia Gelissen,Naomi Adjei,Blair McNamara,Levent Mutlu,Justin Harold,Mitchell Clark,Gary Altwerger,Peter Dottino,Gloria S. Huang,Alessandro D. Santin,Masoud Azodi,Elena Ratner,Peter E. Schwartz,Vaagn Andikyan
标识
DOI:10.1245/s10434-023-13757-0
摘要
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality evidence currently only supports the use of HIPEC with cisplatin at the time of interval cytoreduction after neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Many questions remain, including HIPEC's role at other timepoints in ovarian cancer treatment, who are optimal candidates, and specifics of HIPEC protocols. This article reviews the history of normothermic and hyperthermic intraperitoneal chemotherapy in ovarian cancer and evidence regarding HIPEC implementation and patient outcomes. Additionally, this review explores details of HIPEC technique and perioperative care, cost considerations, complication and quality of life data, disparities in HIPEC use, and unresolved issues.
科研通智能强力驱动
Strongly Powered by AbleSci AI